Navigation Links
PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Date:3/5/2012

ANNAPOLIS, Md., March 5, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the ROTH 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Event:

24th Annual ROTH ConferenceDate:

Monday, March 12, 2012 at 5:30 pm Place:

Ritz-Carlton Laguna Niguel, Salon 1Time:

5:30 pm PTAbout PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit www.PharmAthene.com.


    '/>"/>
    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
    3. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    4. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    5. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    6. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    7. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    9. PharmAthene Completes $6.5 Million Registered Direct Offering
    10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    11. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
    (Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
    (Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
    (Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
    Breaking Biology Technology:
    (Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
    (Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
    (Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
    Breaking Biology News(10 mins):